title: Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
abstract: BACKGROUND
  Chronic hyperglycemia has an adverse influence on beta-cell function, which is known as 'glucotoxicity'. Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower the blood glucose concentration by enhancing urinary glucose excretion. This study was performed to clarify the influence of the SGLT2 inhibitor ipragliflozin on beta-cell function assessed from the plasma intact proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
  
  
  METHODS
  This was a 24-week, prospective, single-center, open-label, single-arm study. The subjects were 19 Japanese patients with type 2 diabetes. After a 4- to 8-week period of lifestyle modification, ipragliflozin (50 mg/d) was added to their existing treatment. At baseline and at 12 and 24 weeks after starting ipragliflozin treatment, a meal test was performed to evaluate the fasting and 2-hour proinsulin/C-peptide ratio.
  
  
  RESULTS
  After 24 weeks, the body mass index, fasting plasma glucose, and hemoglobin A1c were all decreased significantly. Both the fasting and 2-hour proinsulin/C-peptide ratio decreased significantly from 25.0 ± 18.9 × 10-3to 14.3 ± 9.0 × 10-3and from 23.2 ± 14.9 × 10-3to 13.7 ± 5.4 × 10-3, respectively (both p < 0.01 vs. baseline).
  
  
  CONCLUSIONS
  These findings indicate that ipragliflozin might have a beneficial effect on beta-cells.
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , Kawasaki , Japan.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Nagai
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , Kawasaki , Japan.
authors.forename: Akio
authors.initials: A
authors.lastname: Ohta
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , Kawasaki , Japan.
authors.forename: Yukiyoshi
authors.initials: Y
authors.lastname: Sada
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , Kawasaki , Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kato
authors.affiliation: a Division of Metabolism and Endocrinology, Department of Internal Medicine , St. Marianna University School of Medicine , Kawasaki , Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000187:drug effects; D002096:C-Peptide / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005947:Glucose / Q000378:metabolism; D005960:Glucosides / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011384:Proinsulin / Q000378:metabolism; D011446:Prospective Studies; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D005947:Glucose; D005960:Glucosides; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D011384:Proinsulin; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes; C089180:SLC5A2 protein, human; C572941:ipragliflozin
keywords: Beta-cell function; Japanese; ipragliflozin; proinsulin/C-peptide ratio; sodium glucose cotransporter 2 inhibitors; type 2 diabetes